Clinical trial · Interventional
Doxil and Gemcitabine in Recurrent Ovarian Cancer
A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer
NCT00312650CI-TRIAL-00016590terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| liposomal doxorubicin and gemcitabine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- rate of hand-foot syndrome
Secondary outcomes (1)
- measure
- objective response rate
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * recurrent platinum resistant ovarian cancer * measurable disease Exclusion Criteria: * prior treatment with Doxil or Gemzar * life expectancy \<3months * cardiac ejection fraction \<50%
References
Publications (0)
Data not yet available
No reference posted for this study.